Antiangiogenic effects of marine sponge derived compounds on cancer.

The term "angiogenic switch" refers to a time-restricted event during tumor progression where the balance between pro- and anti-angiogenic factors, resulting in the transition from dormant avascularized hyperplasia to outgrowing vascularized tumor and eventually to malignant tumor progression. Targeting angiogenesis and its mechanistic pathways are critical target for cancer therapy. Recently, marine derived compounds, plays major role in cancer research. Several sponge derived compounds such as alkaloids, terpenes, macrocylic lactone and polyketide are leading drugs in the treatment of different types of diseases including cancer. Those marine sponge compounds inhibit cancer cell proliferation and tumor angiogenesis. Hence, this review sheds light on angiogenic regulators and marine sponge derived antiangiogenic compounds for cancer.

[1]  Tian-bao Wang,et al.  Serum vascular endothelial growth factor‐C and lymphoangiogenesis are associated with the lymph node metastasis and prognosis of patients with colorectal cancer , 2011, ANZ journal of surgery.

[2]  N. Ferrara.  Vascular endothelial growth factor. , 1993, Trends in cardiovascular medicine.

[3]  Ingeborg Stalmans,et al.  Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. , 2002, The Journal of clinical investigation.

[4]  Hiroshi Yamamoto,et al.  Structure-activity relationship and biological property of cortistatins, anti-angiogenic spongean steroidal alkaloids. , 2007, Bioorganic & medicinal chemistry.

[5]  A. Nakagawara,et al.  Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. , 2001, Gynecologic oncology.

[6]  Hirohisa Yano,et al.  Angiogenesis in Cancer , 2006, Vascular health and risk management.

[7]  G. Sledge,et al.  A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. , 2003, Seminars in oncology.

[8]  Janet Rossant,et al.  Endothelial cells and VEGF in vascular development , 2005, Nature.

[9]  Douglas B. Evans.  Preoperative chemoradiation for pancreatic cancer. , 2005, Seminars in oncology.

[10]  N. Bouck,et al.  Multiple forms of angiostatin induce apoptosis in endothelial cells. , 1998, Blood.

[11]  K. Chayama,et al.  Vascular endothelial growth factor-C expression predicts lymph node metastasis of human gastric carcinomas invading the submucosa. , 2002, European journal of cancer.

[12]  Min Zhao,et al.  Antiangiogenesis effects of endostatin in retinal neovascularization. , 2013, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[13]  Jeffrey W. Clark,et al.  Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  K. Alitalo,et al.  Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. , 2002, Cancer research.

[15]  K. Alitalo,et al.  Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[17]  M. Karkkainen,et al.  The Specificity of Receptor Binding by Vascular Endothelial Growth Factor-D Is Different in Mouse and Man* , 2001, The Journal of Biological Chemistry.

[18]  E. Tschachler,et al.  Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. , 1998, Cancer research.

[19]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[20]  Tina N. Davis,et al.  Vascular endothelial growth factor C is increased in endometrium and promotes endothelial functions, vascular permeability and angiogenesis and growth of endometriosis , 2013, Angiogenesis.

[21]  W. Figg,et al.  The use of thalidomide in androgen-independent prostate cancer. , 2006, Urologic oncology.

[22]  I. Giannopoulou,et al.  Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma. , 2007, European Journal of Surgical Oncology.

[23]  Thomas Hawighorst,et al.  Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis , 2001, Nature Medicine.

[24]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[25]  G. Watanabe,et al.  The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer , 2001, British Journal of Cancer.

[26]  Han‐Chung Wu,et al.  Anti-Angiogenic Therapeutic Drugs for Treatment of Human Cancer , 2008 .

[27]  A. Mercer,et al.  Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus , 1994, Journal of virology.

[28]  R. Goldberg.  Advances in the treatment of metastatic colorectal cancer. , 2005, The oncologist.

[29]  G. Semenza.  Signal transduction to hypoxia-inducible factor 1. , 2002, Biochemical pharmacology.

[30]  D. Faulkner,et al.  Marine natural products. , 1996, Natural product reports.

[31]  D. Faulkner.  Marine natural products (1999) , 2001 .

[32]  Matthew Z. DeMaere,et al.  Functional genomic signatures of sponge bacteria reveal unique and shared features of symbiosis , 2010, The ISME Journal.

[33]  K. Alitalo,et al.  Vascular endothelial growth factor B, a novel growth factor for endothelial cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Yasuo Watanabe,et al.  Cortistatins A, B, C, and D, anti-angiogenic steroidal alkaloids, from the marine sponge Corticium simplex. , 2006, Journal of the American Chemical Society.

[35]  P. Black,et al.  Angiostatin suppresses malignant glioma growth in vivo. , 1998, Cancer research.

[36]  K. Alitalo,et al.  A Recombinant Mutant Vascular Endothelial Growth Factor-C that Has Lost Vascular Endothelial Growth Factor Receptor-2 Binding, Activation, and Vascular Permeability Activities* , 1998, The Journal of Biological Chemistry.

[37]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[38]  Claudio Campa,et al.  Targeting VEGF-A to treat cancer and age-related macular degeneration. , 2007, Annual review of medicine.

[39]  K. Alitalo,et al.  Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. , 1998, The American journal of pathology.

[40]  R. Kiss,et al.  Cyclic versus Hemi-Bastadins. Pleiotropic Anti-Cancer Effects: from Apoptosis to Anti-Angiogenic and Anti-Migratory Effects , 2013, Molecules.

[41]  J. Folkman,et al.  Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[42]  R. Timpl,et al.  The Minimal Active Domain of Endostatin Is a Heparin-Binding Motif that Mediates Inhibition of Tumor Vascularization , 2004, Cancer Research.

[43]  Dexin Kong,et al.  Antiproliferative and Antiangiogenic Activities of Smenospongine, a Marine Sponge Sesquiterpene Aminoquinone , 2011, Marine drugs.

[44]  D. Youssef,et al.  Subereamolline A as a Potent Breast Cancer Migration, Invasion and Proliferation Inhibitor and Bioactive Dibrominated Alkaloids from the Red Sea Sponge Pseudoceratina arabica , 2012, Marine drugs.

[45]  M. Nomura,et al.  Placenta Growth Factor and Vascular Endothelial Growth Factor B and C Expression in Microvascular Endothelial Cells and Pericytes , 1999, The Journal of Biological Chemistry.

[46]  J M Gallo,et al.  Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. , 2001, Cancer research.

[47]  S. Rafii,et al.  Splitting vessels: Keeping lymph apart from blood , 2003, Nature Medicine.

[48]  Tyler A. Johnson,et al.  A reassignment of (-)-mycothiazole and the isolation of a related diol. , 2006, Journal of natural products.

[49]  Beverly A. Teicher,et al.  A systems approach to cancer therapy , 1996, Cancer and Metastasis Reviews.

[50]  M. Kojiro,et al.  Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma , 2004, Cancer.

[51]  A. Vollmar,et al.  Spongistatin 1: a new chemosensitizing marine compound that degrades XIAP , 2008, Leukemia.

[52]  H. Long.  Current research directions for locally advanced cervix cancer , 2003, Current oncology reports.

[53]  P. Crews,et al.  A selective account of effective paradigms and significant outcomes in the discovery of inspirational marine natural products. , 2009, Journal of natural products.

[54]  R. Garlantézec,et al.  VEGFR1 and NRP1 endothelial expressions predict distant relapse after radical prostatectomy in clinically localized prostate cancer. , 2013, Anticancer research.

[55]  E. J. Lee,et al.  Hypoxic priming of mESCs accelerates vascular-lineage differentiation through HIF1-mediated inverse regulation of Oct4 and VEGF , 2012, EMBO molecular medicine.

[56]  R. K. Bright,et al.  VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours , 1999, British Journal of Cancer.

[57]  T. Usui,et al.  Synthesis and Anti-Angiogenic Activity of Cortistatin Analogs , 2008, Bioscience, biotechnology, and biochemistry.

[58]  A. Hongo,et al.  Vascular endothelial growth factor-C expression and its relationship to pelvic lymph node status in invasive cervical cancer , 2001, British Journal of Cancer.

[59]  D. Newman,et al.  Natural products as sources of new drugs over the last 25 years. , 2007, Journal of natural products.

[60]  Patrick England,et al.  A short synthetic peptide inhibits signal transduction, migration and angiogenesis mediated by Tie2 receptor , 2004, EMBO reports.

[61]  L. Vahdat,et al.  Eribulin mesylate for the treatment of breast cancer , 2010, Expert opinion on pharmacotherapy.

[62]  S. Yamashina,et al.  Cyclo‐oxygenase‐2 enhances basic fibroblast growth factor‐induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants , 2000, British journal of pharmacology.

[63]  T. Veikkola,et al.  Interaction of endostatin with integrins implicated in angiogenesis. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[64]  Wentao Yan,et al.  Numerical Simulation of the Inhibitory Effect of Angiostatin on Metastatic Tumor Angiogenesis and Microenvironment , 2013, Bulletin of mathematical biology.

[65]  M. Stack,et al.  Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. , 1999, The Biochemical journal.

[66]  S. Zea,et al.  Does the Odor from Sponges of the Genus Ircinia Protect Them from Fish Predators? , 2002, Journal of Chemical Ecology.

[67]  K. Chayama,et al.  Clinical Significance of Vascular Endothelial Growth Factor C Expression and Angiogenesis at the Deepest Invasive Site of Advanced Colorectal Carcinoma , 2002, Oncology.

[68]  D. Charnock-Jones,et al.  Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma , 2003, British Journal of Cancer.

[69]  B. Fingleton,et al.  Matrix metalloproteinases: biologic activity and clinical implications. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  J. Folkman,et al.  ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS , 1971, The Journal of experimental medicine.

[71]  A. Karsan,et al.  Inhibition of tumor cell invasion and angiogenesis by motuporamines. , 2001, Cancer research.

[72]  G. Kay,et al.  Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. , 2000, Circulation research.

[73]  M. Hammond,et al.  Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610 , 2003, Radiation oncology.

[74]  M. Medina,et al.  Antiangiogenic activity of aeroplysinin‐1, a brominated compound isolated from a marine sponge , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[75]  M. Shibuya,et al.  Bastadin 6, a spongean brominated tyrosine derivative, inhibits tumor angiogenesis by inducing selective apoptosis to endothelial cells , 2006, Anti-cancer drugs.

[76]  H. Ngan,et al.  Proliferation to apoptosis ratio as a prognostic marker in adenocarcinoma of uterine cervix. , 2004, Gynecologic oncology.

[77]  S. Eccles,et al.  C-erbB receptors in squamous cell carcinomas of the head and neck: clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors. , 2002, Oral oncology.

[78]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[79]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[80]  M. Medina,et al.  The Antiangiogenic Compound Aeroplysinin-1 Induces Apoptosis in Endothelial Cells by Activating the Mitochondrial Pathway , 2012, Marine drugs.

[81]  J. Braekman,et al.  Primary cultures from the marine sponge Xestospongia muta (Petrosiidae, Haplosclerida). , 2003, Journal of biotechnology.

[82]  S. Zahler,et al.  Investigation of the marine compound spongistatin 1 links the inhibition of PKCα translocation to nonmitotic effects of tubulin antagonism in angiogenesis , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[83]  S. Fox,et al.  The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[84]  I. Kostova,et al.  Antiangiogenic effects of flavonoids and chalcones. , 2008, Pharmacological research.

[85]  J. Tramper,et al.  Marine Sponges as Pharmacy , 2005, Marine Biotechnology.

[86]  Tyler A. Johnson,et al.  The marine sponge metabolite mycothiazole: a novel prototype mitochondrial complex I inhibitor. , 2010, Bioorganic & medicinal chemistry.

[87]  Lance A. Liotta,et al.  Cancer: Out of air is not out of action , 2003, Nature.

[88]  Motomasa Kobayashi,et al.  Synthesis of BC-ring model of globostellatic acid X methyl ester, an anti-angiogenic substance from marine sponge. , 2008, Bioorganic & medicinal chemistry letters.

[89]  M. Shibuya,et al.  A Novel Type of Vascular Endothelial Growth Factor, VEGF-E (NZ-7 VEGF), Preferentially Utilizes KDR/Flk-1 Receptor and Carries a Potent Mitotic Activity without Heparin-binding Domain* , 1998, The Journal of Biological Chemistry.

[90]  P. Carmeliet.  Angiogenesis in health and disease , 2003, Nature Medicine.